Characteristics of patients, their donors, and transplantation, 1988 to 2006
| . | Donor age, years . | ||
|---|---|---|---|
| 18 to 32 . | 33 to 50 . | >50 . | |
| Number | 2260 | 3651 | 438 |
| Donor characteristics | |||
| Donor-recipient HLA-match | |||
| 8/8 matched | 1443 (64%) | 2066 (57%) | 224 (51%) |
| 7/8 matched | 487 (22%) | 960 (26%) | 137 (31%) |
| 6/8 matched | 216 (10%) | 421 (12%) | 50 (11%) |
| 5/8 matched or lower | 114 (5%) | 204 (6%) | 27 (6%) |
| Donor-recipient ABO match | |||
| Matched | 946 (42%) | 1529 (42%) | 180 (41%) |
| Minor mismatch | 591 (26%) | 885 (24%) | 115 (26%) |
| Major mismatch | 697 (31%) | 1157 (32%) | 137 (31%) |
| Not reported | 26 (1%) | 80 (2%) | 6 (1%) |
| Donor sex and parity | |||
| Male | 1338 (59%) | 2349 (64%) | 256 (58%) |
| Female, nulliparous | 639 (28%) | 297 (8%) | 24 (5%) |
| Female, parity, 1 or more | 256 (11%) | 957 (26%) | 155 (35%) |
| Not reported | 27 (1%) | 48 (1%) | 3 (1%) |
| Donor-recipient cytomegalovirus serostatus | |||
| Donor and recipient negative | 771 (34%) | 1080 (30%) | 114 (26%) |
| Donor negative, recipient positive | 788 (35%) | 1187 (33%) | 101 (23%) |
| Donor and recipient positive | 412 (18%) | 747 (20%) | 128 (29%) |
| Donor positive, recipient positive | 246 (11%) | 550 (15%) | 82 (19%) |
| Not reported | 43 (2%) | 87 (2%) | 13 (3%) |
| Patient characteristics | |||
| Patient age, years | |||
| <18 | 410 (18%) | 610(17%) | 55 (13%) |
| 18-45 | 1086 (48%) | 1807 (49%) | 240 (55%) |
| >45 | 764 (34%) | 1234 (34%) | 143 (33%) |
| Performance score | |||
| <90 | 598 (26%) | 967 (26%) | 117 (27%) |
| 90 or 100 | 1485 (66%) | 2426 (66%) | 290 (66%) |
| Not reported | 177 (8%) | 258 (7%) | 31 (7%) |
| Disease | |||
| Acute myeloid leukemia | 966 (43%) | 1407 (39%) | 160 (37%) |
| Acute lymphoblastic leukemia | 543 (24%) | 847 (23%) | 103 (24%) |
| Chronic myeloid leukemia | 531 (23%) | 1074 (29%) | 133 (30%) |
| Myelodysplastic syndrome | 220 (10%) | 323 (9%) | 42 (10%) |
| Donor status at transplantation | |||
| 1st complete remission/chronic phase | 913 (40%) | 1527 (42%) | 183 (42%) |
| 2nd complete remission/chronic/accelerated phase | 665 (29%) | 1088 (30%) | 123 (28%) |
| Relapse/blast phase/refractory anemia excessblasts | 682 (30%) | 1036 (28%) | 132 (30%) |
| Transplant characteristics | |||
| Conditioning regimen | |||
| Myeloablative | |||
| Total body irradiation containing | 1325 (58%) | 2270 (63%) | 273 (63%) |
| Non–irradiation containing | 631 (28%) | 940 (26%) | 116 (26%) |
| Reduced intensity | |||
| Low-dose total body irradiation containing | 86 (4%) | 115 (2%) | 12 (3%) |
| Non–irradiation containing | 218 (10%) | 326 (9%) | 37 (8%) |
| GVHD prophylaxis | |||
| Tacrolimus-containing | 1025 (46%) | 1552 (43%) | 194 (45%) |
| Cyclosporine-containing | 1235 (54%) | 2099 (57%) | 244 (55%) |
| In vivo T-cell depletion | |||
| Yes | 484 (22%) | 721 (20%) | 80 (18%) |
| None | 1776 (79%) | 2930 (80%) | 358 (82%) |
| Graft type | |||
| Bone marrow | 1351 (60%) | 2348 (64%) | 267 (61%) |
| Peripheral blood | 909 (40%) | 1303 (36%) | 171 (39%) |
| Cell dose | |||
| Bone marrow, total nucleated cells <3 × 108/kg | 686 (30%) | 1276 (35%) | 161 (37%) |
| Bone marrow, total nucleated cells ≥3 × 108/kg | 661 (29%) | 1054 (29%) | 104 (24%) |
| Peripheral blood, CD34 <4.5 × 106/kg | 286 (13%) | 451 (12%) | 66 (15%) |
| Peripheral blood, CD34 ≥4.5 × 106/kg | 603 (27%) | 824 (23%) | 96 (22%) |
| Not reported | 24 (1%) | 46 (1%) | 11 (3%) |
| Transplant period | |||
| 1987-2002 | 1082 (48%) | 1980 (54%) | 233 (53%) |
| 2003-2006 | 1178 (52%) | 1671 (46%) | 205 (47%) |
| Follow-up, median (range), months | 113 (6-290) | 119 (5-312) | 121 (8-290) |
| . | Donor age, years . | ||
|---|---|---|---|
| 18 to 32 . | 33 to 50 . | >50 . | |
| Number | 2260 | 3651 | 438 |
| Donor characteristics | |||
| Donor-recipient HLA-match | |||
| 8/8 matched | 1443 (64%) | 2066 (57%) | 224 (51%) |
| 7/8 matched | 487 (22%) | 960 (26%) | 137 (31%) |
| 6/8 matched | 216 (10%) | 421 (12%) | 50 (11%) |
| 5/8 matched or lower | 114 (5%) | 204 (6%) | 27 (6%) |
| Donor-recipient ABO match | |||
| Matched | 946 (42%) | 1529 (42%) | 180 (41%) |
| Minor mismatch | 591 (26%) | 885 (24%) | 115 (26%) |
| Major mismatch | 697 (31%) | 1157 (32%) | 137 (31%) |
| Not reported | 26 (1%) | 80 (2%) | 6 (1%) |
| Donor sex and parity | |||
| Male | 1338 (59%) | 2349 (64%) | 256 (58%) |
| Female, nulliparous | 639 (28%) | 297 (8%) | 24 (5%) |
| Female, parity, 1 or more | 256 (11%) | 957 (26%) | 155 (35%) |
| Not reported | 27 (1%) | 48 (1%) | 3 (1%) |
| Donor-recipient cytomegalovirus serostatus | |||
| Donor and recipient negative | 771 (34%) | 1080 (30%) | 114 (26%) |
| Donor negative, recipient positive | 788 (35%) | 1187 (33%) | 101 (23%) |
| Donor and recipient positive | 412 (18%) | 747 (20%) | 128 (29%) |
| Donor positive, recipient positive | 246 (11%) | 550 (15%) | 82 (19%) |
| Not reported | 43 (2%) | 87 (2%) | 13 (3%) |
| Patient characteristics | |||
| Patient age, years | |||
| <18 | 410 (18%) | 610(17%) | 55 (13%) |
| 18-45 | 1086 (48%) | 1807 (49%) | 240 (55%) |
| >45 | 764 (34%) | 1234 (34%) | 143 (33%) |
| Performance score | |||
| <90 | 598 (26%) | 967 (26%) | 117 (27%) |
| 90 or 100 | 1485 (66%) | 2426 (66%) | 290 (66%) |
| Not reported | 177 (8%) | 258 (7%) | 31 (7%) |
| Disease | |||
| Acute myeloid leukemia | 966 (43%) | 1407 (39%) | 160 (37%) |
| Acute lymphoblastic leukemia | 543 (24%) | 847 (23%) | 103 (24%) |
| Chronic myeloid leukemia | 531 (23%) | 1074 (29%) | 133 (30%) |
| Myelodysplastic syndrome | 220 (10%) | 323 (9%) | 42 (10%) |
| Donor status at transplantation | |||
| 1st complete remission/chronic phase | 913 (40%) | 1527 (42%) | 183 (42%) |
| 2nd complete remission/chronic/accelerated phase | 665 (29%) | 1088 (30%) | 123 (28%) |
| Relapse/blast phase/refractory anemia excessblasts | 682 (30%) | 1036 (28%) | 132 (30%) |
| Transplant characteristics | |||
| Conditioning regimen | |||
| Myeloablative | |||
| Total body irradiation containing | 1325 (58%) | 2270 (63%) | 273 (63%) |
| Non–irradiation containing | 631 (28%) | 940 (26%) | 116 (26%) |
| Reduced intensity | |||
| Low-dose total body irradiation containing | 86 (4%) | 115 (2%) | 12 (3%) |
| Non–irradiation containing | 218 (10%) | 326 (9%) | 37 (8%) |
| GVHD prophylaxis | |||
| Tacrolimus-containing | 1025 (46%) | 1552 (43%) | 194 (45%) |
| Cyclosporine-containing | 1235 (54%) | 2099 (57%) | 244 (55%) |
| In vivo T-cell depletion | |||
| Yes | 484 (22%) | 721 (20%) | 80 (18%) |
| None | 1776 (79%) | 2930 (80%) | 358 (82%) |
| Graft type | |||
| Bone marrow | 1351 (60%) | 2348 (64%) | 267 (61%) |
| Peripheral blood | 909 (40%) | 1303 (36%) | 171 (39%) |
| Cell dose | |||
| Bone marrow, total nucleated cells <3 × 108/kg | 686 (30%) | 1276 (35%) | 161 (37%) |
| Bone marrow, total nucleated cells ≥3 × 108/kg | 661 (29%) | 1054 (29%) | 104 (24%) |
| Peripheral blood, CD34 <4.5 × 106/kg | 286 (13%) | 451 (12%) | 66 (15%) |
| Peripheral blood, CD34 ≥4.5 × 106/kg | 603 (27%) | 824 (23%) | 96 (22%) |
| Not reported | 24 (1%) | 46 (1%) | 11 (3%) |
| Transplant period | |||
| 1987-2002 | 1082 (48%) | 1980 (54%) | 233 (53%) |
| 2003-2006 | 1178 (52%) | 1671 (46%) | 205 (47%) |
| Follow-up, median (range), months | 113 (6-290) | 119 (5-312) | 121 (8-290) |